These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 2018816

  • 1. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
    Pigott TA, Zohar J, Hill JL, Bernstein SE, Grover GN, Zohar-Kadouch RC, Murphy DL.
    Biol Psychiatry; 1991 Mar 01; 29(5):418-26. PubMed ID: 2018816
    [Abstract] [Full Text] [Related]

  • 2. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
    Broocks A, Pigott TA, Hill JL, Canter S, Grady TA, L'Heureux F, Murphy DL.
    Psychiatry Res; 1998 Jun 02; 79(1):11-20. PubMed ID: 9676822
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
    Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL.
    Biol Psychiatry; 1993 Jan 01; 33(1):3-14. PubMed ID: 8420593
    [Abstract] [Full Text] [Related]

  • 4. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.
    Mueller EA, Murphy DL, Sunderland T.
    Psychopharmacology (Berl); 1986 Jan 01; 89(3):388-91. PubMed ID: 3014595
    [Abstract] [Full Text] [Related]

  • 5. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
    Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR.
    Arch Gen Psychiatry; 1992 Jan 01; 49(1):21-8. PubMed ID: 1728249
    [Abstract] [Full Text] [Related]

  • 6. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
    Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR.
    Arch Gen Psychiatry; 1989 Jan 01; 46(1):23-8. PubMed ID: 2910220
    [Abstract] [Full Text] [Related]

  • 7. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
    Zohar J, Insel TR.
    Biol Psychiatry; 1987 Jun 01; 22(6):667-87. PubMed ID: 3036259
    [Abstract] [Full Text] [Related]

  • 8. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
    Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL.
    Arch Gen Psychiatry; 1987 Nov 01; 44(11):946-51. PubMed ID: 3675134
    [Abstract] [Full Text] [Related]

  • 9. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
    Khanna S, John JP, Reddy LP.
    Psychoneuroendocrinology; 2001 Feb 01; 26(2):209-23. PubMed ID: 11087965
    [Abstract] [Full Text] [Related]

  • 10. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR.
    Arch Gen Psychiatry; 1988 Feb 01; 45(2):177-85. PubMed ID: 3337615
    [Abstract] [Full Text] [Related]

  • 11. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
    Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR.
    Biol Psychiatry; 1995 Aug 01; 38(3):138-49. PubMed ID: 7578657
    [Abstract] [Full Text] [Related]

  • 12. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
    Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR.
    Psychiatry Res; 1991 Jan 01; 36(1):1-17. PubMed ID: 2017519
    [Abstract] [Full Text] [Related]

  • 13. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
    Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW.
    Biol Psychiatry; 1991 Nov 15; 30(10):973-84. PubMed ID: 1756202
    [Abstract] [Full Text] [Related]

  • 14. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
    Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J.
    Neuropsychobiology; 2004 Nov 15; 50(3):200-5. PubMed ID: 15365215
    [Abstract] [Full Text] [Related]

  • 15. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
    de Leeuw AS, Westenberg HG.
    J Psychiatr Res; 2008 Sep 15; 42(11):894-901. PubMed ID: 18533183
    [Abstract] [Full Text] [Related]

  • 16. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder.
    Murphy DL, Zohar J, Benkelfat C, Pato MT, Pigott TA, Insel TR.
    Br J Psychiatry Suppl; 1989 Dec 15; (8):15-24. PubMed ID: 2692636
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects.
    Kahn RS, Kalus O, Wetzler S, Cahn W, Asnis GM, van Praag HM.
    Psychiatry Res; 1990 Aug 15; 33(2):189-98. PubMed ID: 2243896
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
    Hollander E, Kwon J, Weiller F, Cohen L, Stein DJ, DeCaria C, Liebowitz M, Simeon D.
    Psychiatry Res; 1998 Jul 13; 79(3):213-7. PubMed ID: 9704868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.